Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop (Second from left)
Managing Director & CEO, Paul Hyslop (Second from left)
Source: Zoono Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against COVID-19
  • Laboratory tests show the product is more than 99.99 per cent effective against the virus
  • Z-71 is the same technology used in the company’s hand sanitiser
  • Zoono’s products are known to protect humans against a variety of viruses for up to 30 days on surfaces and 24 hours on hands
  • Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share

Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against the recent coronavirus (COVIOD-19).

Laboratory tests show the product is more than 99.99 per cent effective against the virus.

COVID-19 has become a global concern and has been shown to survive on surfaces for up to nine days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Z-71 was previously tested against bovine coronavirus, however, this latest strain required new testing.

The company conducted two separate tests to EN Standard 14476:2013+A2:2019 for chemical disinfectants and antiseptics.

EN14476 is the European Standard that applies to products within the medical area, this includes hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding and others.

Z-71 Microbe Shield is the same technology used in the company’s hand sanitisers.

“Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus,” the company told the market.

Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share at 11:31 am AEDT.

zno by the numbers
More From The Market Online

Argent Biopharma executes global licence for non-core Cannabis genetics

Argent BioPharma has entered into a worldwide licensing agreement with TPI for the commercial development of…

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…